Children need champions. Get involved, speak out, volunteer, or become a donor and give every child a fair chance to succeed.
Library Home | Reset filters
Select one or more filter options and click search below.
Reset filters
AUTHOR(S) Faith Agbozo; Albrecht Jahn
AUTHOR(S) José Moreno-Montoya; Silvia Marcela Ballesteros; Jaid Constanza Rojas Sotelo (et al.)
This article aims to assess the impact of the COVID-19 pandemic on routine childhood vaccination coverage in Colombia by age group, rural/urban residence, state and vaccine type. It is an ecological study of official monthly vaccination records.
AUTHOR(S) Chloe A. Teasdale; Luisa N. Borrell; Yanhan Shen (et al.)
AUTHOR(S) Kaidi He; Wendy J. Mack; Michael Neely (et al.)
AUTHOR(S) Tom Woudenberg; Stephane Pelleau; Francois Anna (et al.)
AUTHOR(S) Beate Kampmann; Uduak Okomo
AUTHOR(S) Katy Lillie
AUTHOR(S) Adin Breuer; Allon Raphael; Hagay Stern (et al.)
This study evaluated the prevalence of paediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections using antibody testing and characterised antibody titres by time from exposure. This was a single-centre, prospective, cross-sectional cohort study. Patients under 18 years old were eligible to participate if they attended the paediatric emergency department at the tertiary Shaare Zedek Medical Center, Jerusalem, Israel, from 18 October 2020 to 12 January 2021 and required blood tests or intravenous access. SARS-CoV-2 seropositivity and antibody levels were tested by a dual-assay model.
AUTHOR(S) S. Bookstein Peretz; N. Regev; L. Novick (et al.)
This study aims to determine the immunogenicity and reactogenicity of Pfizer's BNT162b2 COVID-19 vaccine among pregnant women compared with non-pregnant women, and to evaluate the obstetric outcome following vaccination. An observational case-control study of pregnant women, who were vaccinated by a 2-dose regimen of BNT162b2 vaccine during gestation between January-February 2021 (study group) and were compared to age-matched non-pregnant women who received the vaccine during the same time period (control group).
AUTHOR(S) Kenneth J. Smith; Angela R. Wateska; Mary Patricia Nowalk (et al.)
AUTHOR(S) Lindsay A. Thompson; Sonja A. Rasmussen
Nearly 4 million children in the US have been infected with COVID-19 as of May 2021. While most children have had mild or no symptoms, thousands have been hospitalized and several hundred have died. Children with underlying conditions are more likely to experience severe effects of COVID-19, but even healthy children can be severely affected. Children can spread COVID-19 to others and also can have long-term effects that last months. For these reasons, children need to be protected from COVID-19. Currently, 3 vaccines are authorized for adults in the United States. In studies of tens of thousands of people, these vaccines were safe and effective. The vaccine made by Pfizer was recently authorized for children 12 years and older. Two doses of this vaccine are recommended to be given 3 weeks apart. The other 2 vaccines were authorized for persons 18 years and older but are expected to be available for teenagers soon. Studies in younger children as young as age 6 months are ongoing and if these studies show that they are safe and effective, vaccines could be available for children 6 months and older by late 2021 or early 2022.
AUTHOR(S) Daniel Glikman; Michal Stein; Eric S. Shinwell
AUTHOR(S) Fernando Barros; Fernando P. Hartwig; Aluísio J. D. Barros (et al.)
The purpose of this study is to estimate the prevalence of SARS-CoV-2 antibodies and the adherence to measures of social distancing in children and adolescents studied in three national surveys conducted in Brazil between May–June 2020. Three national serological surveys were conducted in 133 sentinel cities located in all 27 Federative Units. Multistage probability sampling was used to select 250 individuals per city. The total sample size in age ranges 0–9 and 10–19 years old are of 4,263 and 8,024 individuals, respectively. Information on children or adolescents was gathered with a data collection app, and a rapid point-of-case test for SARS-CoV-2 was conducted on a finger prick blood sample.
AUTHOR(S) Carol C. Chen; Anne Whitehead
Although the disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) seems to be less common and less severe in children, it remains unclear what role pediatric populations play in the spread of the virus. The understanding of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection is continuing to evolve, and guidelines for evaluation and treatment may depend on local and institutional recommendations. Emergency providers can play an important role in advocating for public health in the form of vaccine advocacy and education. While still rare, emergency providers must also consider nonendemic, mostly tropical infections in children presenting with fever who are recently returning from international travel.
AUTHOR(S) James A. Connelly; Hey Chong; Adam J. Esbenshade (et al.)
UNICEF Innocenti's Children and COVID-19 Library is a database collecting research from around the world on COVID-19 and its impacts on children and adolescents.
Read the latest quarterly digest on violence against children and women during COVID-19.
The first digest covers children and youth mental health under COVID-19.
Subscribe to updates on new research about COVID-19 & children
COVID-19 & Children: Rapid Research Response
